摘要
目的：观察洛铂联合依托泊苷治疗初治食管小细胞癌的疗效。方法16例初治食管小细胞癌患者全部使用洛铂与依托泊苷联合化疗方案治疗。结果完全缓解（CR）5例，占31．3％，部分缓解（PR）6例，占37．5％，稳定（SD）4例，占25％，进展（PD）1例，占6．25％，总有效率（ORR）68．8％。Ⅰ～Ⅳ度不良反应发生率以疲倦最高，全部患者均有程度不等的疲倦。贫血占41．7％，白细胞下降占39．7％，血小板下降占20．9％，厌食、恶心、呕吐占29．3％，ALT、AST 升高占14．5％，除白细胞下降外均为轻至中度反应。结论洛铂是一种安全有效的第三代铂类抗肿瘤药物，患者耐受性好，临床中可尝试应用于食管小细胞癌患者。
Objective To observe curative effect of lobaplatin plus etoposide,the new antitumor platinum drugs,on the untreated esophageal small cell of carcinoma.Methods Sixteen patients with esophageal small cell of carcinoma were treated using the lobaplatin/vp16 regimen.Results The complete response （CR） rates were 31.3%,partial response （PR）rates were 37.5%,stable disease （SD）rates were 25%,progressive disease （PD） rates were 6.25%,overall response rate （ORR）68.8%.Languor was the most common symptom in the grade -ⅠtoⅣ adverse reactions.All patients had symptoms of languor.Other related symptoms included the anaemia （41.7%）, leukocytopenia （39.7%）,thrombocytopenia （20.9%）,anorexia,vomiting,nausea （29.3%）and increase of ALT and AST （14.5%）.The toxic effect was not serious damage.Conclusion Lobaplatin is a new and safe antitumor platinum drug with a promising clinical effect,has a good tolerance in patients,and it can try to be used in the patients who have esophageal small cell of carcinoma.
出处
《中国基层医药》
CAS
2015年第16期2470-2472,共3页
Chinese Journal of Primary Medicine and Pharmacy
关键词
洛铂
依托泊苷
化疗
食管小细胞癌
Lobaplation
Etoposide
Chemotherapy
Esophageal small cell of carcinoma
